BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21061792)

  • 21. [Concurrent chemoradiation therapy with nedaplatin for high-risk cervical cancer--clinical investigation of adverse events].
    Kamiura S; Kobayashi K; Ohira H; Seino H; Hashimoto N; Sawai K; Samejima Y; Saji F
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):979-86. PubMed ID: 11478148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
    Zhang P; Feng FY; Wu LY; Hu Y; Liu JW; Gao YJ; Guan XQ; Nan KJ; Suo AL; Wang XW; Zhang MH; Zhang WD; Li CW; Zhang Y; Zhao JB
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):230-4. PubMed ID: 16875614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma.
    Adachi S; Ogasawara T; Wakimoto E; Tsuji Y; Takemura T; Koyama K; Takayasu Y; Inoue J; Nakao N
    Cancer; 2001 Jan; 91(1):74-9. PubMed ID: 11148562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
    Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
    Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution.
    Kinjyo Y; Nagai Y; Toita T; Kudaka W; Ariga T; Shimoji Y; Nakasone T; Taira Y; Arakaki Y; Nakamoto T; Wakayama A; Ooyama T; Maemoto H; Heianna J; Aoki Y
    Br J Radiol; 2017 Aug; 90(1076):20170241. PubMed ID: 28707541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin (CDGP) and 5-FU with concurrent radiotherapy for advanced oral cancer].
    Aoki K; Tatebayashi S; Imai Y; Yamakawa N; Yagyuu T; Kajihara A; Nakagawa H; Kirita T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1777-81. PubMed ID: 18030010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Concurrent chemoradiotherapy for advanced cervical cancer--a pilot study].
    Kodama J; Hashimoto I; Seki N; Hongo A; Mizutani Y; Miyagi Y; Yoshinouchi M; Kudo T
    Gan To Kagaku Ryoho; 2001 Mar; 28(3):351-5. PubMed ID: 11265403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study.
    Yokoyama Y; Takano T; Nakahara K; Shoji T; Sato H; Yamada H; Yaegashi N; Okamura K; Kurachi H; Sugiyama T; Tanaka T; Sato A; Tase T; Mizunuma H
    Oncol Rep; 2008 Jun; 19(6):1551-6. PubMed ID: 18497964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC). A phase I/II and pharmacokinetic study.
    Micheletti E; La Face B; Bianchi E; Cagna E; Apostoli P; Ruggeri G; Verardi R; Sartori E
    Am J Clin Oncol; 1997 Dec; 20(6):613-20. PubMed ID: 9391552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
    Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
    Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of serum platinum of gynecologic cancer patients treated with nedaplatin.
    Matsumoto Y; Ishiko O; Nakagawa E; Sumi T; Hyun Y; Ando Y; Ogita S
    Oncol Rep; 2001; 8(6):1269-73. PubMed ID: 11605047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chemotherapy intensity importance in concurrent chemoradiotherapy of locally advanced cervical cancer].
    Sirák I; Petera J; Odrázka K; Dolezel M; Zoul Z; Vaculíková M
    Ceska Gynekol; 2006 Jul; 71(4):308-11. PubMed ID: 16956043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer].
    Maruoka Y; Ando T; Hoshino M; Ogiuchi Y; Nishihara N; Okamoto T; Fukada K; Kuwazawa T; Ogiuchi H
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):421-5. PubMed ID: 11915732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials.
    Ma S; Wang J; Han Y; Guo F; Chen C; Chen X; Zou W
    Gynecol Oncol; 2019 Jul; 154(1):246-252. PubMed ID: 31005286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.
    Shimada M; Sato S; Oishi T; Itamochi H; Kigawa J; Takeshima N; Aoki D; Aoki Y; Nambu Y; Ochiai K
    Int J Clin Oncol; 2016 Oct; 21(5):969-974. PubMed ID: 27142771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
    Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
    Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
    J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer.
    Adachi S; Ogasawara T; Tsubamoto H; Oku H; Hori Y; Tsuji Y; Takemura T; Koyama K
    Int J Clin Pharmacol Res; 2001; 21(3-4):105-10. PubMed ID: 12067139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.